Coral Laboratories Ltd
Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Revenue (FOB Value of Exports) ₹ lakhs ・Standalone data |
|
||||||||||
| Permanent Employees on Rolls Number ・Standalone data |
|||||||||||
| Revenue from Ethiopia ₹ lakhs ・Standalone data |
|||||||||||
| Revenue from India ₹ lakhs ・Standalone data |
|||||||||||
| Revenue from Rest of World ₹ lakhs ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Coral Laboratories’ 44th AGM resolutions, including dividend and director reappointments, passed with requisite majority.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Coral Laboratories held 44th AGM on September 29, 2026; approved audited financials, final dividend, and director reappointments.
- Closure of Trading Window
-
Board Meeting Outcome for Considered And Approved Cost Audit Report In CRA-3 For The Financial Year 2025-26
- Board approved Cost Audit Report in CRA-3 for FY 2025-26 on September 25, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
CLL is an ISO 9001:2008 certified manufacturer and exporter of pharmaceutical formulations like tablets, capsules, liquid, and topical preparations. It focuses on generics, troubleshooting existing products, and patent noninfringing products for emerging markets.